Pilulka Lekarny AS (XPRA:PINK) Beneish M-Score: -2.69 (As of Jun. 28, 2026)


XPRA:PINK Pilulka Lekarny AS XPRA:PINK
49 GF Score
Price Kč115.00
GF Value Kč114.69
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Pilulka Lekarny AS Beneish M-Score?

Pilulka Lekarny AS XPRA:PINK -4.17% 49 Beneish M-Score is -2.69 as of Jun. 28, 2026. GuruFocus rates XPRA:PINK with a GF Score™ of 49/100 and a GF Value™ of Kč114.69 (Fairly Valued). The stock has 6 warning signs investors should review. Among 630 Healthcare Providers & Services companies, Pilulka Lekarny AS ranks better than 59.37% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.69 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Pilulka Lekarny AS's Beneish M-Score or its related term are showing as below:

XPRA:PINK' s Beneish M-Score Range Over the Past 10 Years
Min: -4.79   Med: -3.32   Max: 52.83
Current: -2.69

During the past 6 years, the highest Beneish M-Score of Pilulka Lekarny AS was 52.83. The lowest was -4.79. And the median was -3.32.

Pilulka Lekarny AS Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Pilulka Lekarny AS's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pilulka Lekarny AS Beneish M-Score Chart

Pilulka Lekarny AS Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 52.83 -3.95 -4.79 -2.69

Pilulka Lekarny AS Semi-Annual Data
Dec20 Dec21 Dec22 Dec23 Jun24 Dec24 Dec25
Beneish M-Score Get a 7-Day Free Trial 52.83 -3.95 0.00 -4.79 -2.69

Pilulka Lekarny AS Beneish M-Score Competitor Comparison

For the Pharmaceutical Retailers subindustry, Pilulka Lekarny AS's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pilulka Lekarny AS Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pilulka Lekarny AS's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Pilulka Lekarny AS's Beneish M-Score falls into.


XPRA:PINK
49GF Score
Pilulka Lekarny AS XPRA:PINK
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pilulka Lekarny AS Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Pilulka Lekarny AS for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0493+0.528 * 1.9845+0.404 * 0.7631+0.892 * 0.672+0.115 * 0.9503
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * -0.093545-0.327 * 0.835
=-2.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was Kč54 Mil.
Revenue was Kč876 Mil.
Gross Profit was Kč39 Mil.
Total Current Assets was Kč144 Mil.
Total Assets was Kč197 Mil.
Property, Plant and Equipment(Net PPE) was Kč9 Mil.
Depreciation, Depletion and Amortization(DDA) was Kč34 Mil.
Selling, General, & Admin. Expense(SGA) was Kč0 Mil.
Total Current Liabilities was Kč227 Mil.
Long-Term Debt & Capital Lease Obligation was Kč1 Mil.
Net Income was Kč-39 Mil.
Gross Profit was Kč0 Mil.
Cash Flow from Operations was Kč-20 Mil.
 Total Receivables was Kč77 Mil.
Revenue was Kč1,304 Mil.
Gross Profit was Kč115 Mil.
Total Current Assets was Kč146 Mil.
Total Assets was Kč237 Mil.
Property, Plant and Equipment(Net PPE) was Kč21 Mil.
Depreciation, Depletion and Amortization(DDA) was Kč64 Mil.
Selling, General, & Admin. Expense(SGA) was Kč0 Mil.
Total Current Liabilities was Kč327 Mil.
Long-Term Debt & Capital Lease Obligation was Kč2 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(54.391 / 876.423) / (77.14 / 1304.243)
=0.06206 / 0.059145
=1.0493

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(115.114 / 1304.243) / (38.979 / 876.423)
=0.088261 / 0.044475
=1.9845

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (143.72 + 9.005) / 197.146) / (1 - (146.121 + 21.137) / 237.335)
=0.22532 / 0.295266
=0.7631

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=876.423 / 1304.243
=0.672

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(64.294 / (64.294 + 21.137)) / (34.285 / (34.285 + 9.005))
=0.752584 / 0.791984
=0.9503

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 876.423) / (0 / 1304.243)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.2 + 227.235) / 197.146) / ((2.4 + 326.954) / 237.335)
=1.15871 / 1.387718
=0.835

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-38.869 - 0 - -20.427) / 197.146
=-0.093545

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Pilulka Lekarny AS has a M-score of -2.69 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.69 mean?
Pilulka Lekarny AS (XPRA:PINK) has a Beneish M-Score of -2.69 as of Jun. 28, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Pilulka Lekarny AS and its competitors. According to the industry distribution chart, Pilulka Lekarny AS ranks #256 out of 630 companies in the Healthcare Providers & Services industry, placing it in the top 40.6%.
Is Pilulka Lekarny AS's Beneish M-Score too high?
Pilulka Lekarny AS's current Beneish M-Score is -2.69. Based on the distribution chart, Pilulka Lekarny AS ranks #256 out of 630 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Pilulka Lekarny AS has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pilulka Lekarny AS's Beneish M-Score compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Pilulka Lekarny AS ranks #256 out of 630 companies for Beneish M-Score. This puts Pilulka Lekarny AS in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Pilulka Lekarny AS and its competitors. Pilulka Lekarny AS's current Beneish M-Score is -2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pilulka Lekarny AS stock overvalued right now?
Based on GuruFocus' analysis, Pilulka Lekarny AS (XPRA:PINK) is currently considered Fairly Valued. The stock's GF Value™ is Kč114.69, compared to a current price of Kč115.00 — trading 0.3% above its estimated fair value. The current Beneish M-Score is -2.69. Pilulka Lekarny AS's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Pilulka Lekarny AS (XPRA:PINK), the current Beneish M-Score is -2.69 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pilulka Lekarny AS (XPRA:PINK) Overvalued in 2026?

Based on GuruFocus' analysis, Pilulka Lekarny AS stock appears to be overvalued. The current stock price of Kč115.00 is trading 0.3% above its estimated GF Value™ of Kč114.69. GuruFocus considers Pilulka Lekarny AS to be Fairly Valued.

Key valuation signals for XPRA:PINK:

  • Beneish M-Score: -2.69
  • GF Value™: Kč114.69 vs. price of Kč115.00 (0.3% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the XPRA:PINK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pilulka Lekarny AS Business Description

Address Drahobejlova 1073/36, Prague, CZE, 190 00
Pilulka Lekarny AS operates an online pharmaceutical store by distribution of medicinal products. The store offers over-the-counter-drugs, dietary supplements, baby foods, mother care products, cosmetics, other prescription drugs, sport nutritional products, diagnostic test kits, orthopaedic supplies, first aid kits, and other related products.
49GF Score

Get the complete analysis for XPRA:PINK

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Kč115.00
Price
Kč114.69
GF Value